Literature DB >> 20435950

Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis.

Patrice Forget1, Julie Vandenhende, Martine Berliere, Jean-Pascal Machiels, Benoît Nussbaum, Catherine Legrand, Marc De Kock.   

Abstract

BACKGROUND: Whether intraoperative analgesics have an impact on postoperative cancer recurrence is unknown. Some investigations suggest that the opioids could favor relapse and that regional analgesia and nonsteroidal antiinflammatory drugs could improve cancer prognosis. We retrospectively reviewed our series of breast cancer surgery patients.
METHODS: This retrospective study included 327 consecutive women who underwent mastectomy with axillary dissection for breast cancer. The main objective was to compare the incidence of cancer recurrence among patients who received different analgesics during surgery.
RESULTS: Perioperative characteristics, cancer prognostic factors, and the length of surgery were comparable regardless of the analgesics administered. Univariate and multivariate analyses showed a lower cancer recurrence rate when ketorolac was given before surgery (P = 0.019). Other analgesics (sufentanil, ketamine, and clonidine) were not associated with a significant reduction in cancer recurrence rates in our series.
CONCLUSION: This retrospective analysis suggests that intraoperative administration of ketorolac decreases the risk of breast cancer relapse compared with other analgesícs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20435950     DOI: 10.1213/ANE.0b013e3181d2ad07

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  68 in total

Review 1.  The Role of NSAIDs in Breast Cancer Prevention and Relapse: Current Evidence and Future Perspectives.

Authors:  Demetrios Moris; Michalis Kontos; Eleftherios Spartalis; Ian S Fentiman
Journal:  Breast Care (Basel)       Date:  2016-10-24       Impact factor: 2.860

2.  [The effect of peridural analgesia on long-term survival after surgery in patients with colorectal cancer : A systematic meta-analysis].

Authors:  J P N Holler; J Ahlbrandt; M Gruß; A Hecker; M A Weigand; W Padberg; R Röhrig
Journal:  Chirurg       Date:  2015-07       Impact factor: 0.955

3.  Preoperative stimulation of resolution and inflammation blockade eradicates micrometastases.

Authors:  Dipak Panigrahy; Allison Gartung; Jun Yang; Haixia Yang; Molly M Gilligan; Megan L Sulciner; Swati S Bhasin; Diane R Bielenberg; Jaimie Chang; Birgitta A Schmidt; Julia Piwowarski; Anna Fishbein; Dulce Soler-Ferran; Matthew A Sparks; Steven J Staffa; Vidula Sukhatme; Bruce D Hammock; Mark W Kieran; Sui Huang; Manoj Bhasin; Charles N Serhan; Vikas P Sukhatme
Journal:  J Clin Invest       Date:  2019-06-17       Impact factor: 14.808

4.  The R-Enantiomer of Ketorolac Delays Mammary Tumor Development in Mouse Mammary Tumor Virus-Polyoma Middle T Antigen (MMTV-PyMT) Mice.

Authors:  Amanda S Peretti; Dayna Dominguez; Martha M Grimes; Helen J Hathaway; Eric R Prossnitz; Melanie R Rivera; Angela Wandinger-Ness; Donna F Kusewitt; Laurie G Hudson
Journal:  Am J Pathol       Date:  2017-11-21       Impact factor: 4.307

Review 5.  Perioperative events influence cancer recurrence risk after surgery.

Authors:  Jonathan G Hiller; Nicholas J Perry; George Poulogiannis; Bernhard Riedel; Erica K Sloan
Journal:  Nat Rev Clin Oncol       Date:  2017-12-28       Impact factor: 66.675

6.  Anesthetic drug propofol inhibits the expression of interleukin-6, interleukin-8 and cyclooxygenase-2, a potential mechanism for propofol in suppressing tumor development and metastasis.

Authors:  Xuefeng Li; Longyun Li; Feng Liang; Guifeng Liu; Guoqing Zhao
Journal:  Oncol Lett       Date:  2018-04-17       Impact factor: 2.967

7.  A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients.

Authors:  Yuna Guo; S Ray Kenney; Linda Cook; Sarah F Adams; Teresa Rutledge; Elsa Romero; Tudor I Oprea; Larry A Sklar; Edward Bedrick; Charles L Wiggins; Huining Kang; Lesley Lomo; Carolyn Y Muller; Angela Wandinger-Ness; Laurie G Hudson
Journal:  Clin Cancer Res       Date:  2015-06-12       Impact factor: 12.531

Review 8.  Perspectives in anaesthesia for cancer surgery.

Authors:  Patrice Forget; Marc De Kock
Journal:  J Cancer Res Clin Oncol       Date:  2013-09-28       Impact factor: 4.553

Review 9.  Imaging innate immune responses at tumour initiation: new insights from fish and flies.

Authors:  Yi Feng; Paul Martin
Journal:  Nat Rev Cancer       Date:  2015-08-20       Impact factor: 60.716

Review 10.  Chronic opioid therapy in long-term cancer survivors.

Authors:  A Carmona-Bayonas; P Jiménez-Fonseca; E Castañón; A Ramchandani-Vaswani; R Sánchez-Bayona; A Custodio; D Calvo-Temprano; J A Virizuela
Journal:  Clin Transl Oncol       Date:  2016-07-21       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.